All In Biotech

Drug Trial Radar · NCT07340697

Evaluate RLS-1496 Topical Cream for Actinic Keratosis

An Open-Label Clinical Study to Evaluate the Safety and Effect of RLS-1496 Topical Cream for the Treatment of Actinic Keratosis

Last checked: Nov 20, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Feb 3, 2026

Primary completion

May 27, 2026

Study completion Aug 2026

Sponsor

Lead sponsor
Rubedo Life Sciences, Inc.Industry
Sponsor type
Industry
First posted
Jan 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial will assess the safety and tolerability of topical application of RLS-1496 cream to lesions and adjacent skin on the left forearm of adults with actinic keratoses (AK) on the arms. The right forearm will remain untreated as a control. The therapeutic objective of topical treatment with RLS-1496 cream is to clear or decrease the number of AK in the treated area, per lesion counts performed by the Investigator. The main questions it aims to answer are: * Is it safe to apply topical RLS-1496 cream to treat AK once daily for 28 days? * Does topical RLS-1496 lower the number of AKs or eliminate AKs in a treated area when applied once daily for 28 days? Researchers will compare results on the left (treated with RLS-1496) and right (no treatment) forearm. Participants will apply RLS-1496 to an identified area on the left forearm once each day for 28 days and have intermittent clinic visits to examine the arms and have the AK lesions counted until 28 days after the last application of RLS-1496. Participants will also have small skin biopsies on the arms.

Conditions

  • Actinic Keratosis (AK)

Interventions

  • RLS-1496 1.0% creamDrug

    Topical cream to be applied to lesions and peri-lesional skin.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of multiple doses of topical RLS-1496 creamTime frame: 57 days
  2. Proportion of individual AK lesions with complete (100%) clearanceTime frame: 29 days
  3. Complete (100%) clearance of AK lesionsTime frame: 29 days

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Burke Pharmaceutical Research

    Hot Springs, Arkansas

  • Minnesota Clinical Study Center

    New Brighton, Minnesota

  • Schlessinger MD Skin Research Center

    Omaha, Nebraska

  • Austin Institute for Clinical Research

    Pflugerville, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.